A Study of KT-621 Administered Orally to Adults with Moderate to Severe Eosinophilic Asthma
Research type
Research Study
Full title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma
IRAS ID
1013187
Contact name
Sasha Barrate
Contact email
Sponsor organisation
Kymera Therapeutics, Inc.
Clinicaltrials.gov Identifier
Research summary
This trial is being done to learn about a medicine called KT-621. The purpose of the trial is to see if KT-621 is safe and can work in Eosinophilic Asthma. KT-621 is a new investigational drug that is being developed for treating people with uncontrolled moderate to severe Eosinophilic Asthma. Asthma symptoms include inflammation of the airway, wheezing, chest tightness, shortness of breath, and night-time coughing. Eosinophilic Asthma is a type of asthma where a particular white blood cell, called an eosinophil, causes inflammation in the lungs and airways. Eosinophilic Asthma often has more severe symptoms, such as more frequent asthma occurrences, worsening of the asthma, and poor response to medications used to treat asthma, like inhalers.
The goals of the trial are to see if the participants' asthma symptoms get better after taking KT-621 in addition to their current asthma medication, and to see if KT-621 is safe (whether participants have any side effects) and tolerable (how well participants tolerate any side effects that they may have when taking KT-621 daily).
The trial will include about 264 participants from ages 18 to 75. It is planned to run at about 100 sites in about 12 countries.
Participants will be randomly assigned (like flipping a coin) to 1 of 4 groups, which includes different doses of the investigational drug or placebo.
If a participant is eligible, they will be in the trial for up to 21 weeks (consisting of an up-to 5-week screening period followed by a 12-week treatment period, and a follow-up period of 4 weeks). Participants will visit the trial site approximately eight times.
At certain trial visits, they will have blood samples, ECGs, urine tests, lung function tests, and other assessments to make sure they stay healthy. Participants will also need to answer questionnaires using an electronic device.REC name
North West - Haydock Research Ethics Committee
REC reference
25/NW/0371
Date of REC Opinion
22 Jan 2026
REC opinion
Further Information Favourable Opinion